A Randomized, Investigator- /Subject-blind, Single- and Multiple-ascending Dose, Placebo-controlled Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 (Including RO6953958 Effect on Midazolam) Following Oral Administration in Healthy Male Participants
Latest Information Update: 19 Jul 2024
At a glance
- Drugs RO 6953958 (Primary)
- Indications Autistic disorder; Developmental disabilities; Mental disorders; Pervasive child development disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 15 Feb 2022 Status changed from active, no longer recruiting to completed.
- 03 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 24 Nov 2021 Planned End Date changed from 22 Nov 2021 to 6 Feb 2022.